Omnicell, Inc. (NASDAQ:OMCL) Given Average Rating of “Buy” by Brokerages
Omnicell, Inc. (NASDAQ:OMCL) has been given an average recommendation of “Buy” by the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $47.00.
Several analysts have recently commented on OMCL shares. Piper Jaffray Companies lowered shares of Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price target on the stock. in a research report on Friday, April 21st. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $53.00 price target (up previously from $43.00) on shares of Omnicell in a research report on Tuesday, April 25th. CIBC lifted their price target on shares of Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, April 26th. TheStreet lowered shares of Omnicell from a “b-” rating to a “c+” rating in a research report on Thursday, May 4th. Finally, Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th.
In other Omnicell news, Chairman Randall A. Lipps sold 18,200 shares of the business’s stock in a transaction that occurred on Tuesday, April 25th. The stock was sold at an average price of $41.00, for a total value of $746,200.00. Following the sale, the chairman now owns 208,982 shares of the company’s stock, valued at $8,568,262. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Randall A. Lipps sold 31,527 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $42.87, for a total value of $1,351,562.49. Following the completion of the sale, the chairman now directly owns 196,551 shares in the company, valued at approximately $8,426,141.37. The disclosure for this sale can be found here. In the last three months, insiders sold 101,000 shares of company stock worth $4,221,001. 3.75% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Omnicell during the fourth quarter worth about $1,628,000. State Street Corp raised its stake in shares of Omnicell by 8.1% in the fourth quarter. State Street Corp now owns 802,579 shares of the company’s stock worth $27,210,000 after buying an additional 60,375 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Omnicell during the fourth quarter worth about $788,000. Guggenheim Capital LLC raised its stake in shares of Omnicell by 75.4% in the fourth quarter. Guggenheim Capital LLC now owns 48,053 shares of the company’s stock worth $1,628,000 after buying an additional 20,663 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Omnicell by 26.6% in the fourth quarter. AQR Capital Management LLC now owns 24,935 shares of the company’s stock worth $845,000 after buying an additional 5,236 shares during the last quarter. 96.35% of the stock is currently owned by institutional investors.
Shares of Omnicell (OMCL) traded up 0.70% during midday trading on Friday, reaching $43.00. The company’s stock had a trading volume of 28,023 shares. The stock’s 50 day moving average price is $42.12 and its 200 day moving average price is $38.65. The firm’s market cap is $1.60 billion. Omnicell has a one year low of $30.35 and a one year high of $44.60.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, May 4th. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.36. The firm had revenue of $150.90 million for the quarter, compared to analyst estimates of $152.63 million. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. The business’s revenue for the quarter was down 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 EPS. Analysts predict that Omnicell will post $1.28 earnings per share for the current year.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.